Development of a limited-sampling model for prediction of doxorubicin exposure in dogs

Luke Anthony Wittenburg, D. H. Thamm, D. L. Gustafson

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Understanding the relationship between drug dose and exposure (pharmacokinetics, PK) and the relationship between exposure and effect (pharmacodynamics) is an important component of pharmacology when attempting to predict clinical effects of anticancer drugs. PK studies can provide a better understanding of these relationships; however, they often involve intensive sampling over an extended period of time, resulting in increased cost and decreased compliance. Doxorubicin (DOX), one of the most widely used antineoplastic agents in veterinary cancer therapy, is characterized by large interpatient variability in overall drug exposure and the development and degree of myelosuppression following equivalent dosages. We have developed and validated a limited-sampling strategy for DOX, in which three blood samples are obtained over 1 h post-treatment, that accurately predicts patient exposure. This strategy could allow for refining of dosing variables and utilization of therapeutic drug monitoring to ensure optimized dosing.

Original languageEnglish (US)
Pages (from-to)114-119
Number of pages6
JournalVeterinary and Comparative Oncology
Volume12
Issue number2
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

doxorubicin
Doxorubicin
antineoplastic agents
pharmacology
drugs
pharmacokinetics
prediction
Pharmacokinetics
Pharmaceutical Preparations
therapeutics
Drug Monitoring
refining
dosage
sampling
compliance
Antineoplastic Agents
Compliance
Pharmacology
Costs and Cost Analysis
neoplasms

Keywords

  • Adriamycin
  • Canine
  • Limited sampling
  • Pharmacodynamics
  • Pharmacokinetics

ASJC Scopus subject areas

  • veterinary(all)
  • Medicine(all)

Cite this

Development of a limited-sampling model for prediction of doxorubicin exposure in dogs. / Wittenburg, Luke Anthony; Thamm, D. H.; Gustafson, D. L.

In: Veterinary and Comparative Oncology, Vol. 12, No. 2, 2014, p. 114-119.

Research output: Contribution to journalArticle

@article{3529c17384574fbfa4ae6851808dff36,
title = "Development of a limited-sampling model for prediction of doxorubicin exposure in dogs",
abstract = "Understanding the relationship between drug dose and exposure (pharmacokinetics, PK) and the relationship between exposure and effect (pharmacodynamics) is an important component of pharmacology when attempting to predict clinical effects of anticancer drugs. PK studies can provide a better understanding of these relationships; however, they often involve intensive sampling over an extended period of time, resulting in increased cost and decreased compliance. Doxorubicin (DOX), one of the most widely used antineoplastic agents in veterinary cancer therapy, is characterized by large interpatient variability in overall drug exposure and the development and degree of myelosuppression following equivalent dosages. We have developed and validated a limited-sampling strategy for DOX, in which three blood samples are obtained over 1 h post-treatment, that accurately predicts patient exposure. This strategy could allow for refining of dosing variables and utilization of therapeutic drug monitoring to ensure optimized dosing.",
keywords = "Adriamycin, Canine, Limited sampling, Pharmacodynamics, Pharmacokinetics",
author = "Wittenburg, {Luke Anthony} and Thamm, {D. H.} and Gustafson, {D. L.}",
year = "2014",
doi = "10.1111/j.1476-5829.2012.00340.x",
language = "English (US)",
volume = "12",
pages = "114--119",
journal = "Veterinary and Comparative Oncology",
issn = "1476-5829",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Development of a limited-sampling model for prediction of doxorubicin exposure in dogs

AU - Wittenburg, Luke Anthony

AU - Thamm, D. H.

AU - Gustafson, D. L.

PY - 2014

Y1 - 2014

N2 - Understanding the relationship between drug dose and exposure (pharmacokinetics, PK) and the relationship between exposure and effect (pharmacodynamics) is an important component of pharmacology when attempting to predict clinical effects of anticancer drugs. PK studies can provide a better understanding of these relationships; however, they often involve intensive sampling over an extended period of time, resulting in increased cost and decreased compliance. Doxorubicin (DOX), one of the most widely used antineoplastic agents in veterinary cancer therapy, is characterized by large interpatient variability in overall drug exposure and the development and degree of myelosuppression following equivalent dosages. We have developed and validated a limited-sampling strategy for DOX, in which three blood samples are obtained over 1 h post-treatment, that accurately predicts patient exposure. This strategy could allow for refining of dosing variables and utilization of therapeutic drug monitoring to ensure optimized dosing.

AB - Understanding the relationship between drug dose and exposure (pharmacokinetics, PK) and the relationship between exposure and effect (pharmacodynamics) is an important component of pharmacology when attempting to predict clinical effects of anticancer drugs. PK studies can provide a better understanding of these relationships; however, they often involve intensive sampling over an extended period of time, resulting in increased cost and decreased compliance. Doxorubicin (DOX), one of the most widely used antineoplastic agents in veterinary cancer therapy, is characterized by large interpatient variability in overall drug exposure and the development and degree of myelosuppression following equivalent dosages. We have developed and validated a limited-sampling strategy for DOX, in which three blood samples are obtained over 1 h post-treatment, that accurately predicts patient exposure. This strategy could allow for refining of dosing variables and utilization of therapeutic drug monitoring to ensure optimized dosing.

KW - Adriamycin

KW - Canine

KW - Limited sampling

KW - Pharmacodynamics

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84897959975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897959975&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5829.2012.00340.x

DO - 10.1111/j.1476-5829.2012.00340.x

M3 - Article

C2 - 22747489

AN - SCOPUS:84897959975

VL - 12

SP - 114

EP - 119

JO - Veterinary and Comparative Oncology

JF - Veterinary and Comparative Oncology

SN - 1476-5829

IS - 2

ER -